GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » Cyclically Adjusted Revenue per Share

IPA (ImmunoPrecise Antibodies) Cyclically Adjusted Revenue per Share : $0.77 (As of Jan. 2025)


View and export this data going back to 2011. Start your Free Trial

What is ImmunoPrecise Antibodies Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ImmunoPrecise Antibodies's adjusted revenue per share for the three months ended in Jan. 2025 was $0.130. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.77 for the trailing ten years ended in Jan. 2025.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ImmunoPrecise Antibodies was 41.90% per year. The lowest was 4.70% per year. And the median was 12.30% per year.

As of today (2025-04-13), ImmunoPrecise Antibodies's current stock price is $0.4313. ImmunoPrecise Antibodies's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2025 was $0.77. ImmunoPrecise Antibodies's Cyclically Adjusted PS Ratio of today is 0.56.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ImmunoPrecise Antibodies was 26.56. The lowest was 0.45. And the median was 6.75.


ImmunoPrecise Antibodies Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for ImmunoPrecise Antibodies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoPrecise Antibodies Cyclically Adjusted Revenue per Share Chart

ImmunoPrecise Antibodies Annual Data
Trend Dec14 Dec15 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.68 0.75 0.76 0.78

ImmunoPrecise Antibodies Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.78 0.77 0.77 0.77

Competitive Comparison of ImmunoPrecise Antibodies's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunoPrecise Antibodies's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Cyclically Adjusted PS Ratio falls into.


;
;

ImmunoPrecise Antibodies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ImmunoPrecise Antibodies's adjusted Revenue per Share data for the three months ended in Jan. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=0.13/134.0288*134.0288
=0.130

Current CPI (Jan. 2025) = 134.0288.

ImmunoPrecise Antibodies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201701 0.113 102.456 0.148
201704 0.057 103.167 0.074
201707 0.060 103.278 0.078
201710 0.114 104.070 0.147
201801 0.147 104.578 0.188
201804 0.140 105.708 0.178
201807 0.196 106.324 0.247
201810 0.173 106.695 0.217
201901 0.151 106.200 0.191
201904 0.147 107.818 0.183
201907 0.152 108.250 0.188
201910 0.176 108.577 0.217
202001 0.227 108.841 0.280
202004 0.215 108.173 0.266
202007 0.193 109.318 0.237
202010 0.230 109.861 0.281
202101 0.210 110.364 0.255
202104 0.207 112.673 0.246
202107 0.190 115.183 0.221
202110 0.196 116.696 0.225
202201 0.196 118.619 0.221
202204 0.200 121.978 0.220
202207 0.147 125.002 0.158
202210 0.152 125.734 0.162
202301 0.154 126.223 0.164
202304 0.167 127.992 0.175
202307 0.172 128.974 0.179
202310 0.179 129.810 0.185
202401 0.180 130.124 0.185
202404 0.177 132.289 0.179
202407 0.141 132.708 0.142
202410 0.158 133.182 0.159
202501 0.130 134.029 0.130

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


ImmunoPrecise Antibodies  (NAS:IPA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ImmunoPrecise Antibodies's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.4313/0.77
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ImmunoPrecise Antibodies was 26.56. The lowest was 0.45. And the median was 6.75.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ImmunoPrecise Antibodies Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunoPrecise Antibodies Business Description

Industry
Traded in Other Exchanges
Address
3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.